State of Alaska Department of Revenue Sells 135 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

State of Alaska Department of Revenue cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 15,764 shares of the medical research company’s stock after selling 135 shares during the period. State of Alaska Department of Revenue’s holdings in Charles River Laboratories International were worth $2,909,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of CRL. Cetera Investment Advisers increased its stake in shares of Charles River Laboratories International by 2.4% in the 2nd quarter. Cetera Investment Advisers now owns 9,969 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 229 shares during the last quarter. Czech National Bank increased its stake in Charles River Laboratories International by 7.1% in the third quarter. Czech National Bank now owns 10,517 shares of the medical research company’s stock valued at $2,072,000 after purchasing an additional 701 shares in the last quarter. Mather Group LLC. raised its holdings in Charles River Laboratories International by 25.8% in the third quarter. Mather Group LLC. now owns 449 shares of the medical research company’s stock worth $88,000 after purchasing an additional 92 shares during the period. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Charles River Laboratories International during the third quarter worth $79,000. Finally, Fiduciary Financial Group LLC grew its holdings in shares of Charles River Laboratories International by 41.3% in the 3rd quarter. Fiduciary Financial Group LLC now owns 1,602 shares of the medical research company’s stock valued at $299,000 after buying an additional 468 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on CRL shares. Bank of America reduced their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. The Goldman Sachs Group decreased their price objective on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Morgan Stanley dropped their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. JPMorgan Chase & Co. reduced their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a report on Monday, February 3rd. Finally, Evercore ISI raised their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $200.79.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $163.65 on Monday. The stock has a market capitalization of $8.37 billion, a PE ratio of 20.48, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. Charles River Laboratories International, Inc. has a 52 week low of $159.65 and a 52 week high of $275.00. The stock has a 50 day moving average price of $180.61 and a 200 day moving average price of $193.23. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).